Administration of teriparatide for four years cyclically compared to two years daily in treatment Naïve and alendronate treated women.

Cosman F, Nieves JW, Roimisher C, Neubort S, McMahon DJ, Dempster DW, Lindsay R

Bone21 Oct 2018Cited by 16 (Europe PMC)

PMID30355512DOI10.1016/j.bone.2018.10.020PepBankPUB-30355512

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study18

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In treatment-naive women, lumbar spine BMD changes did not differ significantly between cyclic teriparatide over 48 months and daily treatment over 24 months.
In plain wordsIn treatment-naive women, cyclic teriparatide did not change lumbar spine bone density significantly more than daily treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeLumbar spine BMD in treatment-naive women
Study
n: not reported in source
Comparator
Daily teriparatide for 24 months
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Lumbar spine BMD change
8.6%
daily at 24 months
Lumbar spine BMD change
6.9%
cyclic at 48 months
Source sentences
Summary
None of the BMD changes differed significantly between groups but all changes were significant over time within each group (p < 0.01 except for FN where p = 0.17 Daily; p = 0.09 Cyclic).
4 context sentences(design, population, supporting numbers)
Summary · context
In Rx-Naïve, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 8.6% vs. 6.9%; TH 2.5% vs. 2.6%, and FN 1.6% vs. 2.2%.
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
Report a problemFND-3035551201
02HumanRandomized controlled trialEfficacy outcome
In treatment-naive women, total hip BMD changes did not differ significantly between cyclic teriparatide over 48 months and daily treatment over 24 months.
In plain wordsIn treatment-naive women, cyclic teriparatide did not change total hip bone density significantly more than daily treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal hip BMD in treatment-naive women
Study
n: not reported in source
Comparator
Daily teriparatide for 24 months
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Total hip BMD change
2.5%
daily at 24 months
Total hip BMD change
2.6%
cyclic at 48 months
Source sentences
Summary
None of the BMD changes differed significantly between groups but all changes were significant over time within each group (p < 0.01 except for FN where p = 0.17 Daily; p = 0.09 Cyclic).
4 context sentences(design, population, supporting numbers)
Summary · context
In Rx-Naïve, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 8.6% vs. 6.9%; TH 2.5% vs. 2.6%, and FN 1.6% vs. 2.2%.
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
Report a problemFND-3035551202
03HumanRandomized controlled trialEfficacy outcome
In treatment-naive women, femoral neck BMD changes did not differ significantly between cyclic teriparatide over 48 months and daily treatment over 24 months.
In plain wordsIn treatment-naive women, cyclic teriparatide did not change femoral neck bone density significantly more than daily treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD in treatment-naive women
Study
n: not reported in source
Comparator
Daily teriparatide for 24 months
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Femoral neck BMD change
1.6%
daily at 24 months
Femoral neck BMD change
2.2%
cyclic at 48 months
Source sentences
Summary
None of the BMD changes differed significantly between groups but all changes were significant over time within each group (p < 0.01 except for FN where p = 0.17 Daily; p = 0.09 Cyclic).
4 context sentences(design, population, supporting numbers)
Summary · context
In Rx-Naïve, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 8.6% vs. 6.9%; TH 2.5% vs. 2.6%, and FN 1.6% vs. 2.2%.
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
Report a problemFND-3035551203
04HumanRandomized controlled trialEfficacy outcome
In alendronate-treated women, lumbar spine BMD changes did not differ between cyclic teriparatide over 48 months and daily treatment over 24 months.
In plain wordsIn alendronate-treated women, cyclic and daily teriparatide produced similar lumbar spine bone density changes.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeLumbar spine BMD in alendronate-treated women
Study
n: not reported in source
Comparator
Daily teriparatide for 24 months with continued alendronate
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Lumbar spine BMD change
7.5%
daily at 24 months
Lumbar spine BMD change
7.2%
cyclic at 48 months
Source sentences
Summary
There were no differences between groups but all changes were significant within each group (p < 0.01).
4 context sentences(design, population, supporting numbers)
Summary · context
In ALN-Rx, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 7.5% vs. 7.2%; TH 3.8% vs. 4.1%, and FN 3.2% vs. 2.5%.
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
Report a problemFND-3035551204
05HumanRandomized controlled trialEfficacy outcome
In alendronate-treated women, total hip BMD changes did not differ between cyclic teriparatide over 48 months and daily treatment over 24 months.
In plain wordsIn alendronate-treated women, cyclic and daily teriparatide produced similar total hip bone density changes.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal hip BMD in alendronate-treated women
Study
n: not reported in source
Comparator
Daily teriparatide for 24 months with continued alendronate
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Total hip BMD change
3.8%
daily at 24 months
Total hip BMD change
4.1%
cyclic at 48 months
Source sentences
Summary
There were no differences between groups but all changes were significant within each group (p < 0.01).
4 context sentences(design, population, supporting numbers)
Summary · context
In ALN-Rx, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 7.5% vs. 7.2%; TH 3.8% vs. 4.1%, and FN 3.2% vs. 2.5%.
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
Report a problemFND-3035551205
06HumanRandomized controlled trialEfficacy outcome
In alendronate-treated women, femoral neck BMD changes did not differ between cyclic teriparatide over 48 months and daily treatment over 24 months.
In plain wordsIn alendronate-treated women, cyclic and daily teriparatide produced similar femoral neck bone density changes.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD in alendronate-treated women
Study
n: not reported in source
Comparator
Daily teriparatide for 24 months with continued alendronate
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Femoral neck BMD change
3.2%
daily at 24 months
Femoral neck BMD change
2.5%
cyclic at 48 months
Source sentences
Summary
There were no differences between groups but all changes were significant within each group (p < 0.01).
4 context sentences(design, population, supporting numbers)
Summary · context
In ALN-Rx, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 7.5% vs. 7.2%; TH 3.8% vs. 4.1%, and FN 3.2% vs. 2.5%.
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
Report a problemFND-3035551206
07HumanRandomized controlled trialEfficacy outcome
In treatment-naive women, cyclic teriparatide significantly increased lumbar spine BMD from baseline by 6.9% at 48 months.
In plain wordsIn treatment-naive women, lumbar spine bone density increased significantly from baseline with cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCyclic lumbar spine BMD change in treatment-naive women
Study
n = 25
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 48 monthsAs given in this study (human).
Measurements
Lumbar spine BMD change
6.9%
treatment-naive women, cyclic teriparatide at 48 months, change from baseline
Source sentences
Summary
In Rx-Naïve, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 8.6% vs. 6.9%; TH 2.5% vs. 2.6%, and FN 1.6% vs. 2.2%. None of the BMD changes differed significantly between groups but all changes were significant over time within each group (p < 0.01 except for FN wh…
3 context sentences(design, population, supporting numbers)
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
Report a problemFND-3035551208
08HumanRandomized controlled trialEfficacy outcome
In treatment-naive women, cyclic teriparatide significantly increased total hip BMD from baseline by 2.6% at 48 months.
In plain wordsIn treatment-naive women, total hip bone density increased significantly from baseline with cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCyclic total hip BMD change in treatment-naive women
Study
n = 25
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 48 monthsAs given in this study (human).
Measurements
Total hip BMD change
2.6%
treatment-naive women, cyclic teriparatide at 48 months, change from baseline
Source sentences
Summary
In Rx-Naïve, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 8.6% vs. 6.9%; TH 2.5% vs. 2.6%, and FN 1.6% vs. 2.2%. None of the BMD changes differed significantly between groups but all changes were significant over time within each group (p < 0.01 except for FN wh…
3 context sentences(design, population, supporting numbers)
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
Report a problemFND-3035551210
09HumanRandomized controlled trialEfficacy outcome
In treatment-naive women, cyclic teriparatide produced no significant femoral neck BMD change from baseline at 48 months.
In plain wordsIn treatment-naive women, femoral neck bone density did not change significantly from baseline with cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCyclic femoral neck BMD change in treatment-naive women
Study
n = 25
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 48 monthsAs given in this study (human).
Measurements
Femoral neck BMD change
2.2%
treatment-naive women, cyclic teriparatide at 48 months, change from baseline
Source sentences
Summary
None of the BMD changes differed significantly between groups but all changes were significant over time within each group (p < 0.01 except for FN where p = 0.17 Daily; p = 0.09 Cyclic).
4 context sentences(design, population, supporting numbers)
Summary · context
In Rx-Naïve, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 8.6% vs. 6.9%; TH 2.5% vs. 2.6%, and FN 1.6% vs. 2.2%.
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
Report a problemFND-3035551212
10HumanRandomized controlled trialEfficacy outcome
In treatment-naive women, daily teriparatide significantly increased lumbar spine BMD from baseline by 8.6% at 24 months.
In plain wordsIn treatment-naive women, lumbar spine bone density increased significantly from baseline with daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDaily lumbar spine BMD change in treatment-naive women
Study
n = 23
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Lumbar spine BMD change
8.6%
treatment-naive women, daily teriparatide at 24 months, change from baseline
Source sentences
Summary
In Rx-Naïve, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 8.6% vs. 6.9%; TH 2.5% vs. 2.6%, and FN 1.6% vs. 2.2%. None of the BMD changes differed significantly between groups but all changes were significant over time within each group (p < 0.01 except for FN wh…
3 context sentences(design, population, supporting numbers)
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
Report a problemFND-3035551207
11HumanRandomized controlled trialEfficacy outcome
In treatment-naive women, daily teriparatide significantly increased total hip BMD from baseline by 2.5% at 24 months.
In plain wordsIn treatment-naive women, total hip bone density increased significantly from baseline with daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDaily total hip BMD change in treatment-naive women
Study
n = 23
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Total hip BMD change
2.5%
treatment-naive women, daily teriparatide at 24 months, change from baseline
Source sentences
Summary
In Rx-Naïve, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 8.6% vs. 6.9%; TH 2.5% vs. 2.6%, and FN 1.6% vs. 2.2%. None of the BMD changes differed significantly between groups but all changes were significant over time within each group (p < 0.01 except for FN wh…
3 context sentences(design, population, supporting numbers)
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
Report a problemFND-3035551209
12HumanRandomized controlled trialEfficacy outcome
In treatment-naive women, daily teriparatide produced no significant femoral neck BMD change from baseline at 24 months.
In plain wordsIn treatment-naive women, femoral neck bone density did not change significantly from baseline with daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeDaily femoral neck BMD change in treatment-naive women
Study
n = 23
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Femoral neck BMD change
1.6%
treatment-naive women, daily teriparatide at 24 months, change from baseline
Source sentences
Summary
None of the BMD changes differed significantly between groups but all changes were significant over time within each group (p < 0.01 except for FN where p = 0.17 Daily; p = 0.09 Cyclic).
4 context sentences(design, population, supporting numbers)
Summary · context
In Rx-Naïve, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 8.6% vs. 6.9%; TH 2.5% vs. 2.6%, and FN 1.6% vs. 2.2%.
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
Report a problemFND-3035551211

Studies that did not test the peptide alone6

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

13HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In alendronate-treated women, daily teriparatide with continued alendronate significantly increased lumbar spine BMD from baseline by 7.5% at 24 months.
In plain wordsIn alendronate-treated women, lumbar spine bone density increased from baseline with daily teriparatide plus alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDaily lumbar spine BMD change with alendronate
Study
n = 21
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Lumbar spine BMD change
7.5%
alendronate-treated women, daily teriparatide plus alendronate at 24 months, change from baseline
Source sentences
Summary
In ALN-Rx, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 7.5% vs. 7.2%; TH 3.8% vs. 4.1%, and FN 3.2% vs. 2.5%. There were no differences between groups but all changes were significant within each group (p < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3035551213
14HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In alendronate-treated women, daily teriparatide with continued alendronate significantly increased total hip BMD from baseline by 3.8% at 24 months.
In plain wordsIn alendronate-treated women, total hip bone density increased from baseline with daily teriparatide plus alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDaily total hip BMD change with alendronate
Study
n = 21
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Total hip BMD change
3.8%
alendronate-treated women, daily teriparatide plus alendronate at 24 months, change from baseline
Source sentences
Summary
In ALN-Rx, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 7.5% vs. 7.2%; TH 3.8% vs. 4.1%, and FN 3.2% vs. 2.5%. There were no differences between groups but all changes were significant within each group (p < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3035551215
15HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In alendronate-treated women, daily teriparatide with continued alendronate significantly increased femoral neck BMD from baseline by 3.2% at 24 months.
In plain wordsIn alendronate-treated women, femoral neck bone density increased from baseline with daily teriparatide plus alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDaily femoral neck BMD change with alendronate
Study
n = 21
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Femoral neck BMD change
3.2%
alendronate-treated women, daily teriparatide plus alendronate at 24 months, change from baseline
Source sentences
Summary
In ALN-Rx, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 7.5% vs. 7.2%; TH 3.8% vs. 4.1%, and FN 3.2% vs. 2.5%. There were no differences between groups but all changes were significant within each group (p < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3035551217
16HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In alendronate-treated women, cyclic teriparatide with continued alendronate significantly increased lumbar spine BMD from baseline by 7.2% at 48 months.
In plain wordsIn alendronate-treated women, lumbar spine bone density increased from baseline with cyclic teriparatide plus alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCyclic lumbar spine BMD change with alendronate
Study
n = 20
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Lumbar spine BMD change
7.2%
alendronate-treated women, cyclic teriparatide plus alendronate at 48 months, change from baseline
Source sentences
Summary
In ALN-Rx, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 7.5% vs. 7.2%; TH 3.8% vs. 4.1%, and FN 3.2% vs. 2.5%. There were no differences between groups but all changes were significant within each group (p < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3035551214
17HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In alendronate-treated women, cyclic teriparatide with continued alendronate significantly increased total hip BMD from baseline by 4.1% at 48 months.
In plain wordsIn alendronate-treated women, total hip bone density increased from baseline with cyclic teriparatide plus alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCyclic total hip BMD change with alendronate
Study
n = 20
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Total hip BMD change
4.1%
alendronate-treated women, cyclic teriparatide plus alendronate at 48 months, change from baseline
Source sentences
Summary
In ALN-Rx, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 7.5% vs. 7.2%; TH 3.8% vs. 4.1%, and FN 3.2% vs. 2.5%. There were no differences between groups but all changes were significant within each group (p < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3035551216
18HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In alendronate-treated women, cyclic teriparatide with continued alendronate significantly increased femoral neck BMD from baseline by 2.5% at 48 months.
In plain wordsIn alendronate-treated women, femoral neck bone density increased from baseline with cyclic teriparatide plus alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCyclic femoral neck BMD change with alendronate
Study
n = 20
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Femoral neck BMD change
2.5%
alendronate-treated women, cyclic teriparatide plus alendronate at 48 months, change from baseline
Source sentences
Summary
In ALN-Rx, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 7.5% vs. 7.2%; TH 3.8% vs. 4.1%, and FN 3.2% vs. 2.5%. There were no differences between groups but all changes were significant within each group (p < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25).
Summary · context
In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20).
Summary · context
The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3035551218

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT00668941

Cyclic Versus Daily Teriparatide on Bone Mass

Helen Hayes Hospitaln = 140Sept 2005 to est. Nov 2017

Osteoporosis

Trial page ClinicalTrials.govUpdated 10 Aug 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.